insiderwall
Menu
Superinvestor
Taysha Gene Therapies Inc. TSHA

Super Investor & Insider

1
Fondi che lo detengono
#1301
Rank consenso
1.4%
% dei portafogli
$1.4M
Valore detenuto
Fondo% portaf.AttivitàAzioniValore
Polen Capital Management · Polen Capital Management0.01%Add 104.2%319,748$1.4M

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effecti

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees99
TickerTSHA

Statistics

Market Cap$1.78B
Revenue (TTM)$9.8M
Net Income-$109.0M
Net Margin-1115.3%
EPS$-0.34
P/E2.53
P/S219.63
P/B6.59
EV/EBITDA-10.90
ROE-97.3%
Dividend Yield
Price$6.18

Data: Twelve Data · Revenue = mcap / P/S